Some cancers may not require immediate treatment, from prostate cancer to thyroid tumors. Medical experts share when ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...

A low prognostic nutritional index may indicate a reduced response to ICIs due to diminished hepatic function and systemic inflammation.

An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 6, 2026, Alpha Tau Medical reported final results from its ...

Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...

Participants of the IAEA's MEDBIODOSE coordinated research project at the first research coordination meeting in October 2017, Vienna, Austria ...

As of Monday, January 05, Zenas BioPharma, Inc.’s ZBIO share price has dipped by 53.83%, which has investors questioning if ...

Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

The global cancer drugs market is surging toward $594.3 billion by 2035 as high-tech immunotherapies begin to replace traditional chemotherapy[1]. With response rates now exceeding 90% in some ...

Asal Shirazi, Founder of ASA Foundation, shares insights into what drives inflammatory responses, including the role of ...